株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Anchor Therapeutics, Inc.の製品パイプライン分析

Anchor Therapeutics, Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 255996
出版日 ページ情報 英文 27 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
Anchor Therapeutics, Inc.の製品パイプライン分析 Anchor Therapeutics, Inc. - Product Pipeline Review - 2015
出版日: 2015年09月09日 ページ情報: 英文 27 Pages
概要

Anchor Therapeutics, Inc.は米国に本社を置く製薬企業で、Gタンパク質共役型受容体のペプチドモジュレーターを開発しています。癌、心疾患、炎症、疼痛などが主な治療分野です。

当レポートでは、Anchor Therapeutics, Inc.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Anchor Therapeutics, Inc.の基本情報

  • Anchor Therapeutics, Inc.の概要
  • 主要情報
  • 企業情報

Anchor Therapeutics, Inc.:R&Dの概要

  • 主な治療範囲

Anchor Therapeutics, Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Anchor Therapeutics, Inc.:パイプライン製品の概況

  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Anchor Therapeutics, Inc.:薬剤プロファイル

  • ANC-39
  • ATI-2341
  • Synthetic Peptide 2 to Modulate GPCR for Oncology
  • Synthetic Peptide to Modulate GPCR for Oncology And Metabolic Disorders
  • Synthetic Peptide 1 to Modulate GPCR for Inflammation
  • Synthetic Peptide 1 to Modulate GPCR for Oncology
  • Synthetic Peptide 2 to Modualte GPCR for Inflammation
  • Synthetic Peptide to Modualte Apelin Receptor for Cardiovascular Disorders
  • Synthetic Peptide to Modualte GPCR for Gastrointestinal Disorders
  • Synthetic Peptide to Modualte GPCR for Pain
  • Synthetic Peptide to Modulate GPCR for Endocrine Disorders

Anchor Therapeutics, Inc.:パイプライン分析

  • 標的別
  • 分子タイプ別
  • 作用機序別

Anchor Therapeutics, Inc.:本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07555CDB

Summary

Global Markets Direct's, 'Anchor Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Anchor Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Anchor Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Anchor Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Anchor Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Anchor Therapeutics, Inc.'s pipeline products

Reasons to buy

  • Evaluate Anchor Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Anchor Therapeutics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Anchor Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Anchor Therapeutics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Anchor Therapeutics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Anchor Therapeutics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Anchor Therapeutics, Inc. Snapshot
    • Anchor Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Anchor Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Anchor Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Anchor Therapeutics, Inc. - Pipeline Products Glance
    • Anchor Therapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Anchor Therapeutics, Inc. - Drug Profiles
    • ANC-39
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ATI-2341
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide 1 to Modulate GPCR for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide 1 to Modulate GPCR for Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide 2 to Modulate GPCR for Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide 2 to Modulate GPCR for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide to Modulate Apelin Receptor for Cardiovascular Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptides to Modulate GPR81 for Metabolic Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Anchor Therapeutics, Inc. - Pipeline Analysis
  • Anchor Therapeutics, Inc. - Pipeline Products by Target
  • Anchor Therapeutics, Inc. - Pipeline Products by Molecule Type
  • Anchor Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • Anchor Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Anchor Therapeutics, Inc., Key Information
  • Anchor Therapeutics, Inc., Key Facts
  • Anchor Therapeutics, Inc. - Pipeline by Indication, 2015
  • Anchor Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Anchor Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Anchor Therapeutics, Inc. - Preclinical, 2015
  • Anchor Therapeutics, Inc. - Discovery, 2015
  • Anchor Therapeutics, Inc. - Pipeline by Target, 2015
  • Anchor Therapeutics, Inc. - Pipeline by Molecule Type, 2015
  • Anchor Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015

List of Figures

  • Anchor Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015
  • Anchor Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Anchor Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Anchor Therapeutics, Inc. - Pipeline by Top 10 Target, 2015
  • Anchor Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Anchor Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top